Top

Published in:

01-07-2016 | Original Article

Correlation of Cyfra 21-1 levels in saliva and serum with CK19 mRNA expression in oral squamous cell carcinoma

Authors: Rewa Malhotra, Aadithya B. Urs, Anita Chakravarti, Suman Kumar, V. K. Gupta, Bhawna Mahajan

Published in: Tumor Biology | Issue 7/2016

Abstract

Oral squamous cell carcinoma (OSCC) accounts for 90 % of malignant lesions of oral cavity. The study assessed the potential of Cyfra 21-1 as a tumor marker in OSCC. The study included 50 patients of OSCC to evaluate levels of Cyfra 21-1 in serum and saliva by electrochemiluminescent immunoassay (ECLIA) and CK19 messenger RNA (mRNA) expression in tissue by florescent quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR) along with healthy individuals as control. The salivary and serum Cyfra 21-1 levels in patients of OSCC were significantly higher compared to controls (p value < 0.01). There was a 2.75-fold increase in CK19 mRNA expression in OSCC cases compared to controls. A significant positive correlation was found between serum and salivary Cyfra 21-1, serum Cyfra 21-1, and CK19 mRNA expression and between salivary Cyfra 21-1 and CK19 mRNA expression. Among these, correlation between serum and salivary Cyfra 21-1 was highly significant. Salivary and serum Cyfra 21-1 showed significantly elevated levels in grade II OSCC compared to grade I histopathologically. Elevated levels of salivary Cyfra 21-1 were associated with recurrence in OSCC patients. Reverse operating curve constructed using 3 ng/ml as a cutoff for serum Cyfra 21-1 revealed the sensitivity and specificity to be 88 and 78.2 %, respectively. Using a cutoff value of 8.5 ng/ml for salivary Cyfra 21-1, the sensitivity was found to be 93.8 % and specificity 84.3 %. We advocate salivary Cyfra 21-1 as a better diagnostic marker over serum Cyfra 21-1 as well as a potential marker in the prognosis of OSCC.

American Cancer Society. Cancer Facts and Figures 2007. Atlanta: American Cancer Society 2007.

Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45:309–16.CrossRefPubMed

Markopoulos AK, Michailidou EZ, Tzimagiorgis G. Salivary markers for oral cancer detection. Open Dent J. 2010;4:172–8.CrossRefPubMedPubMedCentral

Zhong LP, Zhang CP, Zheng JW, Li J, Chen WT, Zhang ZY. Increased Cyfra 21-1 concentration in saliva from primary oral squamous cell carcinoma patients. Arch Oral Biol. 2007;52:1079–87.CrossRefPubMed

Doweck I, Barak M, Uri N, Greenberg E. The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer. 2000;83:1696–701.CrossRefPubMedPubMedCentral

Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11–24.CrossRefPubMed

Sawant SS, Zingde SM, Vaidya MM. Cytokeratin fragments in the serum: their utility for the management of oral cancer. Oral Oncol. 2008;44:722–32.CrossRefPubMed

Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem. 2004;37:529–40.CrossRefPubMed

Broers JL, Ramaekers FC, Rot MK, Oostendorp T, Huysmans A, van Muijen GN, et al. Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res. 1988;48:3221–9.PubMed

10.

Bodenmuller H, Ofenloch-Hahnle B, Lane EB, Dessauer A, Bottger V, Donie F. Lung cancer-associated keratin 19 fragments: development and biochemical characterisation of the new serum assay Enzymun-Test CYFRA 21-1. Int J Biol Markers. 1994;9:75–81.PubMed

11.

Dohmoto K, Hojo S, Fujita J, Yang Y, Ueda Y, Bandoh S, et al. The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA 21-1) in human lung cancer cell lines. Int J Cancer. 2001;91:468–73.CrossRefPubMed

12.

Sheard MA, Vojtesek B, Simickova M, Valik D. Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J Cell Biochem. 2002;85:670–7.CrossRefPubMed

13.

Satyam A, Singh P, Sharma M, Seth A, Sharma A. CYFRA 21-1: a potential molecular marker for noninvasive differential diagnosis of urothelial carcinoma of bladder. Biomarkers. 2011;16:413–21.CrossRefPubMed

14.

Cheng B, Rhodus NL, Williams B, Griffin RJ. Detection of apoptotic cells in whole saliva of patients with oral premalignant and malignant lesions: a preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97:465–70.CrossRefPubMed

15.

Wong DT. Salivary diagnostics powered by nanotechnologies, proteomics and genomics. J Am Dent Assoc. 2006;137:313–21.CrossRefPubMed

16.

Vora HH, Shah NG, Patel DD, Trivedi TI, Chikhlikar PR. Prognostic significance of biomarkers in squamous cell carcinoma of the tongue: multivariate analysis. J Surg Oncol. 2003;82:34–50.CrossRefPubMed

17.

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual, 7th ed. New York: Springer, 2010:29–35.

18.

Anneroth G, Batsakis J, Luna M. Review of literature and recommended system of malignancy grading in oral squamous cell carcinoma. Scand J Dent Res. 1987;95:229–49.PubMed

19.

Akhter M, Hossain S, Rahman QB, Molla MR. A study on histological grading of oral squamous cell carcinoma and its co-relationship with regional metastasis. J Oral Maxillofac Pathol. 2011;15:168–76.CrossRefPubMedPubMedCentral

20.

Doshi NP, Shah SA, Patel KB, Jhabuawala MF. Histological grading of oral cancer: a comparison of different systems and their relation to lymph node metastasis. Ntnl J Comm Med. 2011;2:136–42.

21.

Céruse P, Rabilloud M, Charrié A, Dubreuil C, Disant F. Study of cyfra 21-1, a tumor marker, in head and neck squamous cell carcinoma. Ann Otol Rhinol Laryngol. 2005;114:768–76.CrossRefPubMed

22.

Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by Cyfra 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 1993;53:61–6.PubMed

23.

Gadducci A, Ferdeghini M, Cosio S, Fanucchi A, Cristofani R, Genazzani AR. The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer. Int J Gynecol Cancer. 2001;11:277–82.CrossRefPubMed

24.

Al-Shagahin H, Alkotyfan K, Müller HH, Sesterhenn AM, Werner JA. Cyfra 21-1 as a serum tumor marker for follow-up of patients with laryngeal and hypopharyngeal squamous cell carcinoma. Anticancer Res. 2009;29:3421–5.PubMed

25.

Deng YF, Chen P, Lin YZ, Le JZ, Wu XL, Yu MQ, et al. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma. J Laryngol Otol. 2003;117:190–4.PubMed

26.

Doweck I, Barak M, Greenberg E, Uri N, Kellner J, Lurie M, et al. Cyfra 21-1: a new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg. 1995;121:177–81.CrossRefPubMed

27.

Zhong LP, Zhu HG, Zhang CP, Chen WT, Zhang ZY. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma. Int J OralMaxillofac Surg. 2007;36:230–4.CrossRef

28.

Yen TC, Lin WY, Kao CH, Cheng KY, Wang SJ. A study of a new tumour marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin Otolaryngol Allied Sci. 1998;23:82–6.CrossRefPubMed

29.

Nagler R, Bahar G, Shpitzer T, Feinmesser R. Concomitant analysis of salivary tumor markers – a new diagnostic tool for oral cancer. Clin Cancer Res. 2006;12:3979–84.CrossRefPubMed

30.

Rajkumar K, Ramya R, Nandhini G, Rajashree P, Ramesh Kumar A, Nirmala AS. Salivary and serum level of CYFRA 21-1 in oral precancer and oral squamous cell carcinoma. Oral Dis. 2015;21:90–6.CrossRefPubMed

31.

Sánchez-Carbayo M, Espasa A, Chinchilla V, Herrero E, Megías J, Mira A. New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. Clin Chem. 1999;45:1944–53.PubMed

32.

Zhong LP, Zhao SF, Chen GF, Ping FY, Xu ZF, Hu JA. Increased levels of CK19 mRNA in oral squamous cell carcinoma tissue detected by relative quantification with real-time polymerase chain reaction. Arch Oral Biol. 2006;51:1112–9.CrossRefPubMed

33.

Bongers V, Braakhuis BJ, Snow GB. Circulating fragments of cytokeratin 19 in patients with head and neck squamous cell carcinoma. Clin Otolaryngol Allied Sci. 1995;20:479–82.CrossRefPubMed

Title: Correlation of Cyfra 21-1 levels in saliva and serum with CK19 mRNA expression in oral squamous cell carcinoma
Authors: Rewa Malhotra
Aadithya B. Urs
Anita Chakravarti
Suman Kumar
V. K. Gupta
Bhawna Mahajan
Publication date: 01-07-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 7/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-4809-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2016

Raddeanoside R13 inhibits breast cancer cell proliferation, invasion, and metastasis

High expression of constitutive photomorphogenic 1 (COP1) is associated with poor prognosis in bladder cancer

A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with cervical cancer

Elevated STMN1 promotes tumor growth and invasion in endometrial carcinoma

miR-488 acts as a tumor suppressor gene in gastric cancer

Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer